Novo Nordisk is a Denmark-based global healthcare company focused on diabetes, obesity, rare blood disorders and endocrine diseases. Its GLP-1 portfolio gives it a central position in metabolic disease treatment, with growth tied to manufacturing expansion, indication broadening, competition and reimbursement dynamics in major markets.